Ocugen Board Shakeup & Officer Compensation Disclosed
Ticker: OCGN · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1372299
| Field | Detail |
|---|---|
| Company | Ocugen, INC. (OCGN) |
| Form Type | 8-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, officer-compensation
TL;DR
Ocugen director Anya Schiach out, officer pay details filed.
AI Summary
Ocugen, Inc. announced on November 14, 2024, a change in its board of directors. Dr. Anya Schiach, who served as a director, has resigned. The company also disclosed compensatory arrangements for its officers, though specific details and dollar amounts were not provided in this filing.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are crucial for understanding executive incentives.
Risk Assessment
Risk Level: medium — Board changes and compensation disclosures can impact investor confidence and signal potential strategic shifts.
Key Players & Entities
- Ocugen, Inc. (company) — Registrant
- Anya Schiach (person) — Resigned Director
FAQ
When did Dr. Anya Schiach's resignation from the board become effective?
The filing does not specify the exact effective date of Dr. Anya Schiach's resignation, only that it is reported as of November 14, 2024.
What is the primary business of Ocugen, Inc. according to the filing?
Ocugen, Inc. is primarily involved in Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
What is Ocugen's principal executive office address?
Ocugen's principal executive office is located at 11 Great Valley Parkway, Malvern, Pennsylvania 19355.
What specific compensatory arrangements for officers are detailed in this filing?
This filing indicates that compensatory arrangements of certain officers are being disclosed, but the specific details and dollar amounts are not provided within the text of the 8-K itself.
What is Ocugen's fiscal year end?
Ocugen's fiscal year ends on December 31.
Filing Stats: 737 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2024-11-15 16:05:24
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq
Filing Documents
- tm2428543d1_8k.htm (8-K) — 25KB
- 0001104659-24-119698.txt ( ) — 193KB
- ocgn-20241114.xsd (EX-101.SCH) — 3KB
- ocgn-20241114_lab.xml (EX-101.LAB) — 33KB
- ocgn-20241114_pre.xml (EX-101.PRE) — 22KB
- tm2428543d1_8k_htm.xml (XML) — 3KB
02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 14, 2024 (the " Effective Date "), the Board of Directors of Ocugen, Inc. (the " Company ") appointed Ramesh Ramachandran to serve as the Company's principal financial officer and principal accounting officer, effective as of the Effective Date, at which time Michael Breininger, the Company's Corporate Controller, will no longer serve as the principal financial officer and principal accounting officer of the Company. Mr. Ramachandran, age 56, joined the Company in September 2024 as Chief Accounting Officer. Prior to joining the Company, Mr. Ramachandran served as Vice President, Finance & Corporate Controller at Tecomet, Inc., a medical device and aerospace manufacturing solutions company, from May 2022 to August 2024 where he handled the corporate accounting function, including consolidation, reporting, audit, taxes and treasury. From August 2017 to April 2022, Mr. Ramachandran served as Vice President, Finance at Lenox Corporation, a manufacturing company, where he played a pivotal role in the company's sale between private equity firms and led the acquisition and integration of two companies. Prior to that, he served in numerous senior finance roles, including as VP Finance at Virginia Transformer Corp, a transformer manufacturing company, where he handled the corporate finance function, Chief Financial Officer Americas at CG Power Systems, a transformer manufacturing company, where he was responsible for the finance function for the Americas region covering U.S., Canada and Brazil, and Regional Controller and Chief Financial Officer at Xerox HR Solutions (Canada), a company providing human resources services and solutions, where he managed a broad range of financial, reporting and compliance responsibilities. Mr. Ramachandran received his Bachelor of Commerce from Calcutta University and MBA